535 related articles for article (PubMed ID: 25284065)
1. Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.
Urbina JA
J Eukaryot Microbiol; 2015; 62(1):149-56. PubMed ID: 25284065
[TBL] [Abstract][Full Text] [Related]
2. Benznidazole and Posaconazole in Eliminating Parasites in Asymptomatic T. Cruzi Carriers: The STOP-CHAGAS Trial.
Morillo CA; Waskin H; Sosa-Estani S; Del Carmen Bangher M; Cuneo C; Milesi R; Mallagray M; Apt W; Beloscar J; Gascon J; Molina I; Echeverria LE; Colombo H; Perez-Molina JA; Wyss F; Meeks B; Bonilla LR; Gao P; Wei B; McCarthy M; Yusuf S;
J Am Coll Cardiol; 2017 Feb; 69(8):939-947. PubMed ID: 28231946
[TBL] [Abstract][Full Text] [Related]
3. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
[TBL] [Abstract][Full Text] [Related]
4. Nifurtimox versus benznidazole or placebo for asymptomatic Trypanosoma cruzi infection (Equivalence of Usual Interventions for Trypanosomiasis - EQUITY): study protocol for a randomised controlled trial.
Villar JC; Herrera VM; Pérez Carreño JG; Váquiro Herrera E; Castellanos Domínguez YZ; Vásquez SM; Cucunubá ZM; Prado NG; Hernández Y
Trials; 2019 Jul; 20(1):431. PubMed ID: 31307503
[TBL] [Abstract][Full Text] [Related]
5. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F
Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982
[TBL] [Abstract][Full Text] [Related]
6. Role of nucleic acid amplification assays in monitoring treatment response in chagas disease: Usefulness in clinical trials.
Sulleiro E; Muñoz-Calderon A; Schijman AG
Acta Trop; 2019 Nov; 199():105120. PubMed ID: 31376368
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.
Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA
Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138
[TBL] [Abstract][Full Text] [Related]
8. Current drug therapy and pharmaceutical challenges for Chagas disease.
Bermudez J; Davies C; Simonazzi A; Real JP; Palma S
Acta Trop; 2016 Apr; 156():1-16. PubMed ID: 26747009
[TBL] [Abstract][Full Text] [Related]
9. Update in treatment of Chagas disease.
Le Loup G; Pialoux G; Lescure FX
Curr Opin Infect Dis; 2011 Oct; 24(5):428-34. PubMed ID: 21857512
[TBL] [Abstract][Full Text] [Related]
10. Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies.
Sguassero Y; Cuesta CB; Roberts KN; Hicks E; Comandé D; Ciapponi A; Sosa-Estani S
PLoS One; 2015; 10(10):e0139363. PubMed ID: 26436678
[TBL] [Abstract][Full Text] [Related]
11. Ergosterol biosynthesis and drug development for Chagas disease.
Urbina JA
Mem Inst Oswaldo Cruz; 2009 Jul; 104 Suppl 1():311-8. PubMed ID: 19753490
[TBL] [Abstract][Full Text] [Related]
12. Potential new clinical therapies for Chagas disease.
Bustamante JM; Tarleton RL
Expert Rev Clin Pharmacol; 2014 May; 7(3):317-25. PubMed ID: 24716790
[TBL] [Abstract][Full Text] [Related]
13. An update on benznidazole for the treatment of patients with Chagas disease.
Thakare R; Dasgupta A; Chopra S
Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
[TBL] [Abstract][Full Text] [Related]
14. Drug discovery for chagas disease: A viewpoint.
Kratz JM
Acta Trop; 2019 Oct; 198():105107. PubMed ID: 31351074
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease.
Molina I; Gómez i Prat J; Salvador F; Treviño B; Sulleiro E; Serre N; Pou D; Roure S; Cabezos J; Valerio L; Blanco-Grau A; Sánchez-Montalvá A; Vidal X; Pahissa A
N Engl J Med; 2014 May; 370(20):1899-908. PubMed ID: 24827034
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression and Chagas disease: a management challenge.
Pinazo MJ; Espinosa G; Cortes-Lletget C; Posada Ede J; Aldasoro E; Oliveira I; Muñoz J; Gállego M; Gascon J
PLoS Negl Trop Dis; 2013; 7(1):e1965. PubMed ID: 23349998
[TBL] [Abstract][Full Text] [Related]
17. Molecular and biological characterization of a highly pathogenic Trypanosoma cruzi strain isolated from a patient with congenital infection.
Gulin JEN; Bisio M; Rocco DM; Altcheh J; Solana ME; García-Bournissen F
Exp Parasitol; 2018 Mar; 186():50-58. PubMed ID: 29448038
[TBL] [Abstract][Full Text] [Related]
18. Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease.
Filardi LS; Brener Z
Trans R Soc Trop Med Hyg; 1987; 81(5):755-9. PubMed ID: 3130683
[TBL] [Abstract][Full Text] [Related]
19. Chagas disease: Present status of pathogenic mechanisms and chemotherapy.
Maya JD; Orellana M; Ferreira J; Kemmerling U; López-Muñoz R; Morello A
Biol Res; 2010; 43(3):323-31. PubMed ID: 21249304
[TBL] [Abstract][Full Text] [Related]
20. Assessing antibody decline after chemotherapy of early chronic Chagas disease patients.
Murphy N; Cardinal MV; Bhattacharyya T; Enriquez GF; Macchiaverna NP; Alvedro A; Freilij H; Martinez de Salazar P; Molina I; Mertens P; Gilleman Q; Gürtler RE; Miles MA
Parasit Vectors; 2021 Oct; 14(1):543. PubMed ID: 34670602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]